PD-L1 expression in sebaceous carcinomas

Maelle Saliba; Muhammad Shaheen; Rana El Hajj; Fatmeh Abbas; Shaarif Bashir; Umer Nisar Sheikh; Rami Mahfouz; Asif Loya; Ibrahim Khalifeh

doi:10.1007/s00262-020-02821-3

Back

PD-L1 expression in sebaceous carcinomas

Journal article

Peer reviewed

PD-L1 expression in sebaceous carcinomas

Maelle Saliba, Muhammad Shaheen, Rana El Hajj, Fatmeh Abbas, Shaarif Bashir, Umer Nisar Sheikh, Rami Mahfouz, Asif Loya and Ibrahim Khalifeh

Cancer immunology, immunotherapy, Vol.70(7), pp.1907-1915

07/01/2021

DOI: 10.1007/s00262-020-02821-3

PMID: 33398391

View Online

Abstract

Traditional systemic treatments for unresectable, recurrent, and/or advanced sebaceous carcinoma (SC) are ineffective. Tumoral immune microenvironment characterization is essential for considering immune checkpoint inhibitors as a treatment option. A total of 173 resected SCs were reviewed. Clinical information, lesion size, and location were collected. Microscopic examination documented histopathologic features and expression of immunohistochemical markers PD-L1 and CD8. PD-L1 percentage was assessed amongst tumor (PD-L1 + Tu) and immune infiltrating cells (PD-L1 + Inf). Each case was attributed a combined positive score (CPS) following Head and Neck squamous cell carcinoma recommendations. PD-L1 expression was evaluated according to clinicopathologic parameters. Human Papilloma Virus presence (HPV) was analyzed using PCR microarray scanning. A therapeutically relevant CPS was seen in 51.4% of cases. Higher PD-L1 + Tu, PD-L1 + Inf, and CPSs were positively associated with greater lesion size and an extraocular location. No association was seen with patient age or gender. 9.2% of SCs showed PD-L1 + Tu ≥ 1, while 52.0% showed PD-L1 + Inf ≥ 1. A higher CD8 + T-lymphocyte density was significantly associated with a higher CPS, PD-L1 + Tu, and PD-L1 + Inf. Tumor-associated T-cell infiltrate's density was higher along tumor periphery. HPV-16, HPV-43, HPV-52, and HPV-66 were detected in 8.4% of SCs. There was no significant association between HPV status, PD-L1 expression, and CPS. A significant number of SCs express PD-L1 at therapeutic levels. Nevertheless, PD-L1 expression shows a higher intertumoral heterogeneity, in extraocular than in biologically distinct periocular cases. Our data support the need for large-scale prospective studies evaluating anti-PD-L1 immunotherapy mainly in extraocular SC treatment.

Adenocarcinoma, Sebaceous - immunology

Adenocarcinoma, Sebaceous - metabolism

Adenocarcinoma, Sebaceous - pathology

Adolescent

Adult

Aged

Aged, 80 and over

B7-H1 Antigen - metabolism

Biomarkers, Tumor - metabolism

Female

Follow-Up Studies

Humans

Lymphocytes, Tumor-Infiltrating - immunology

Male

Middle Aged

Prognosis

Retrospective Studies

Sebaceous Gland Neoplasms - immunology

Sebaceous Gland Neoplasms - metabolism

Sebaceous Gland Neoplasms - pathology

Tumor Microenvironment - immunology

Young Adult

Details

Title: Subtitle: PD-L1 expression in sebaceous carcinomas
Creators: Maelle Saliba - American University of Beirut Medical Center
Muhammad Shaheen - American University of Beirut Medical Center
Rana El Hajj - American University of Beirut Medical Center
Fatmeh Abbas - American University of Beirut Medical Center
Shaarif Bashir - Shaukat Khanum Memorial Cancer Hospital and Research Center
Umer Nisar Sheikh - Shaukat Khanum Memorial Cancer Hospital and Research Center
Rami Mahfouz - American University of Beirut Medical Center
Asif Loya - Shaukat Khanum Memorial Cancer Hospital and Research Center
Ibrahim Khalifeh - American University of Beirut Medical Center
Resource Type: Journal article
Publication Details: Cancer immunology, immunotherapy, Vol.70(7), pp.1907-1915
DOI: 10.1007/s00262-020-02821-3
PMID: 33398391
ISSN: 0340-7004
eISSN: 1432-0851
Language: English
Date published: 07/01/2021
Academic Unit: Pathology
Record Identifier: 9985217820002771

Metrics

1 Record Views

11 Times Cited - Web of Science